| scholarly article | Q13442814 |
| P2093 | author name string | Paul Sugarbaker | |
| John Spiliotis | |||
| Evgenia Halkia | |||
| P2860 | cites work | Peritoneal carcinomatosis: intra-operative and post-operative assessment of patients undergoing cytoreduction and HIPEC | Q83629648 |
| Intraperitoneal therapy for ovarian cancer: why has it not become standard? | Q83917354 | ||
| Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer | Q84270399 | ||
| Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis | Q84338404 | ||
| The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study | Q84366290 | ||
| Ovarian cancer screening and peritoneal carcinomatosis: standards, 'omics' and miRNAs for personalized management | Q84452101 | ||
| Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients | Q84794962 | ||
| An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) | Q84943384 | ||
| Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis | Q85031023 | ||
| Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer | Q24234736 | ||
| Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer | Q24244876 | ||
| CD95 promotes tumour growth | Q24602589 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Cancer metastasis: building a framework | Q29616783 | ||
| Molecular requirements for epithelial-mesenchymal transition during tumor progression | Q29618960 | ||
| Role of cytoreductive surgery in recurrent ovarian cancer. | Q30378801 | ||
| Clinical and biological significance of tissue transglutaminase in ovarian carcinoma | Q30483685 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study | Q33399902 | ||
| The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. | Q33400589 | ||
| Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer | Q33515642 | ||
| Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. | Q33653799 | ||
| Diffusion-weighted Imaging of Peritoneal Disease for Noninvasive Staging of Advanced Ovarian Cancer | Q33690432 | ||
| Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies | Q33771212 | ||
| 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). | Q33990860 | ||
| Ovarian cancer development and metastasis | Q34086819 | ||
| CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer | Q44212774 | ||
| Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. | Q44407469 | ||
| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
| Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers | Q44816557 | ||
| Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry | Q45376186 | ||
| Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia | Q46114146 | ||
| The clonal evolution of metastases from primary serous epithelial ovarian cancers | Q46611624 | ||
| The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas | Q50168618 | ||
| Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer | Q50169032 | ||
| HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. | Q50788596 | ||
| Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. | Q50794126 | ||
| Learning curve of combined modality treatment in peritoneal surface disease. | Q51980855 | ||
| Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. | Q52123201 | ||
| Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. | Q52911702 | ||
| Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. | Q53227029 | ||
| The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review | Q34363510 | ||
| Cancer of the ovary | Q34375262 | ||
| Staging ovarian cancer: role of imaging | Q34738246 | ||
| Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia | Q34969295 | ||
| Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. | Q35913613 | ||
| Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens | Q35983931 | ||
| Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. | Q36005326 | ||
| Current and future applications of magnetic resonance imaging (MRI) to breast and ovarian cancer patient management | Q36197710 | ||
| The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence | Q36225642 | ||
| Pre-operative evaluation of peritoneal deposits using multidetector computed tomography in ovarian cancer | Q36325099 | ||
| The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. | Q36494563 | ||
| Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer | Q36569460 | ||
| Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma | Q36686192 | ||
| Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival | Q37053323 | ||
| Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis | Q37304407 | ||
| {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. | Q37413723 | ||
| Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review | Q37432638 | ||
| The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer | Q37553639 | ||
| Role of computed tomography in the surgical management of patients with bowel obstruction secondary to recurrent ovarian carcinoma | Q37698524 | ||
| New advances in ovarian cancer. | Q37780737 | ||
| Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. | Q37812968 | ||
| Current and future directions of clinical trials for ovarian cancer | Q37832932 | ||
| A review of cost-effectiveness studies in ovarian cancer | Q37832934 | ||
| Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. | Q37853533 | ||
| Is CA-125 an additional help to radiologic findings for differentiation borderline ovarian tumor from stage I carcinoma? | Q37865952 | ||
| Peritoneal carcinomatosis 2011; it's about time for chemosurgery. | Q37946808 | ||
| Development of an ovarian cancer symptom index: possibilities for earlier detection. | Q39777813 | ||
| Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers | Q40395023 | ||
| Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model | Q40610813 | ||
| Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. | Q41146040 | ||
| The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma | Q41711733 | ||
| Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. | Q42655076 | ||
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece. | Q42659174 | ||
| Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer | Q42928480 | ||
| Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. | Q43064315 | ||
| Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer | Q43142758 | ||
| Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. | Q43593761 | ||
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. | Q43765205 | ||
| Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer | Q43979856 | ||
| Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer. | Q44157108 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. | Q53300225 | ||
| Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. | Q53571926 | ||
| Role of CT in the management of recurrent ovarian cancer. | Q53633561 | ||
| Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. | Q54677737 | ||
| Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer | Q57903781 | ||
| Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial | Q61900008 | ||
| Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival | Q72130912 | ||
| Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer | Q73062082 | ||
| Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy | Q73327577 | ||
| The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer | Q74099954 | ||
| Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study | Q74370777 | ||
| Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial | Q79158185 | ||
| Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer | Q79462945 | ||
| Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma | Q80565368 | ||
| Peritonectomy procedures | Q80620236 | ||
| Intraperitoneal hyperthermic chemotherapy in ovarian cancer | Q81637437 | ||
| Origin of ovarian cancer may have implications for screening | Q82295888 | ||
| CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much? | Q83059715 | ||
| Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan | Q83169031 | ||
| Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial | Q83287534 | ||
| Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis | Q83371433 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| peritoneal carcinomatosis | Q2071182 | ||
| P304 | page(s) | 541842 | |
| P577 | publication date | 2012-07-19 | |
| P1433 | published in | Gastroenterology research and practice | Q26853898 |
| P1476 | title | Diagnosis and management of peritoneal metastases from ovarian cancer | |
| P478 | volume | 2012 |
| Q55244929 | An Unusual Case of Ovarian Carcinomatosis with Microscopic Tumor Embolism Leading to Rectal Ischemia and Perforation. |
| Q35284185 | Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control |
| Q102323090 | COVID-19 free oncologic surgical hub: The experience of reallocation of a gynecologic oncology unit during pandemic outbreak |
| Q100481891 | Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis |
| Q58087069 | Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells |
| Q50213512 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience |
| Q38777716 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer |
| Q52430611 | GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade. |
| Q26744291 | Imaging of peritoneal deposits in ovarian cancer: A pictorial review |
| Q47205866 | Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer |
| Q35003313 | Peritoneal carcinomatosis mimicking a peritoneal tuberculosis |
| Q37644866 | Preclinical activity of melflufen (J1) in ovarian cancer |
| Q40042569 | Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group |
| Q30634871 | Sensitive β-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo |
| Q37513779 | Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells. |
| Q51825430 | Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study. |
| Q48278671 | The peritoneal "soil" for a cancerous "seed": a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. |
| Q26744031 | Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives |
| Q34072226 | Up-regulated FASN expression promotes transcoelomic metastasis of ovarian cancer cell through epithelial-mesenchymal transition |
Search more.